CA
NZ
UK
AU
IND
US
Atmus Filtration Technologies Inc. (NYSE: ATMU) lifted its quarterly cash dividend to $0.06 per common share, up from the prior $0.055 payment. The board’s decision, announced on August 14, 2026, gives investors a higher per‑share cash return and marks the first increase in the …
Bally's Corp reported $792.2 million in quarterly revenue, a 20.5% year-over-year increase, driven by strong growth in its B2C and North America Interactive segments. This growth is expected to drive long-termShareholderreturns, as the company continues to execute on its omni-channel growth strategy.
Beyond Meat, Inc. (NASDAQ: BYND) has executed a reverse stock split with a ratio of 1-for-30, significantly altering its capital structure. As of August 13, 2026, every 30 shares of common stock have been consolidated into one share, aiming to stabilize the stock price …
Edible Garden AG Inc (NASDAQ: EDBL) reported a substantial revenue increase of 12.8%, reaching $3.6 million for the second quarter of 2026, compared to $3.1 million in the same period last year. The impressive figures indicate a strongDemandfor its products, particularly in the cut …
Podcast Spotlights Generational Delay in Marriage
Evolution Metals & Technologies Corp. filed its quarterly report on Form 10-Q with the SEC for the period ended June 30, 2026, disclosing condensed consolidated financial statements and management discussion as of August 17, 2026.
argenx SE (NASDAQ: ARGX) announced that its Phase 3 ALKIVIA trial for Vyvgart Hytrulo in autoimmune myositis achieved its primary objective, with the combined IMNM/DM group demonstrating a statistically significant 15.4-point TIS advantage over placebo at 52 weeks.
OmniAb, Inc. (NASDAQ: OABI) shares rose nearly 18% premarket after the company raised its 2026 year-end cash outlook to $49 million to $53 million, up from $37 million to $41 million, following recent technology licensing and business development activity.
Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) posted third-quarter results that trailed expectations, with a GAAP net loss of $0.34 per share falling $0.09 short of consensus estimates.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) completed itsAcquisitionof Azora Therapeutics, shifting focus to AT177, an oral colon-targeted AhR agonist for ulcerative colitis, while closing the first $32 million tranche of up to $64 million in financing.
Please wait processing your request...